15 mg QD PF-06649751

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03185481 (ClinicalTrials.gov)	July 6, 2017	9/6/2017	Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations	A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-066 ...	Parkinson's Disease With Motor Fluctuations	Drug: 1 mg QDto 15 mg QD PF-06649751;Drug: 3 mg QDto 15 mg QD PF-06649751;Drug: 7 mg QDto 15 mg QD P ...	Pfizer	NULL	Terminated	40 Years	87 Years	All	5	Phase 2	United States
2	NCT02687542 (ClinicalTrials.gov)	March 3, 2016	29/1/2016	Efficacy, Safety and Tolerability of PF-06649751in Parkinson's Disease Patients With Motor Fluctuati ...	A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE ...	Parkinson Disease	Drug: Placebo;Drug: PF-06649751low dose (1 mg QD);Drug: PF-06649751middle dose 1 (3 mg QD);Drug: PF- ...	Pfizer	NULL	Terminated	40 Years	85 Years	All	108	Phase 2	United States;Canada;France;Germany;Japan;Spain

First Previous1Next Last